Ann Dermatol.  2018 Aug;30(4):496-499. 10.5021/ad.2018.30.4.496.

Feasibility of IMP-3 as an Invasiveness Marker for Acral Lentiginous Melanoma

• Seo JW
• Ha SM
• Song KH

• KMID: 2457537
• DOI: http://doi.org/10.5021/ad.2018.30.4.496

Abstract

No abstract available.

MeSH Terms

Melanoma*

Figure

• 

  Fig. 1 Comparison of acral nevus with early acral lentiginous malignant melanoma. (A) Acral nevus, negative (B) acral nevus, weak (C) ALM, weak (D) ALM, moderate, and (E) ALM, strong (H&E, ×200). ALM: acral lentiginous melanoma.

Reference

1. Chang JW, Yeh KY, Wang CH, Yang TS, Chiang HF, Wei FC, et al. Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res. 2004; 14:537–541.

2. Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986–2005. Arch Dermatol. 2009; 145:427–434.

3. Ito T, Moroi Y, Oba J, Nakahara T, Takeuchi S, Uchi H, et al. The prognostic value of a reverse transcriptase-PCR assay of sentinel lymph node biopsy for patients with cutaneous melanoma: a single-center analysis in Japan. Melanoma Res. 2012; 22:38–44.

4. Phan A, Touzet S, Dalle S, Ronger-Savlé S, Balme B, Thomas L. Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol. 2006; 155:561–569.

5. Krementz ET, Feed RJ, Coleman WP 3rd, Sutherland CM, Carter RD, Campbell M. Acral lentiginous melanoma. A clinicopathologic entity. Ann Surg. 1982; 195:632–645.

6. Slingluff CL Jr, Vollmer R, Seigler HF. Acral melanoma: a review of 185 patients with identification of prognostic variables. J Surg Oncol. 1990; 45:91–98.

7. Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 2008; 21:431–437.

8. Yu L, Xu H, Wasco MJ, Bourne PA, Ma L. IMP-3 expression in melanocytic lesions. J Cutan Pathol. 2010; 37:316–322.

9. Sheen YS, Liao YH, Lin MH, Chiu HC, Jee SH, Liau JY, et al. Insulin-like growth factor II mRNA-binding protein 3 expression correlates with poor prognosis in acral lentiginous melanoma. PLoS One. 2016; 11:e0147431.

10. Sheen YS, Liao YH, Lin MH, Chu CY, Ho BY, Hsieh MC, et al. IMP-3 promotes migration and invasion of melanoma cells by modulating the expression of HMGA2 and predicts poor prognosis in melanoma. J Invest Dermatol. 2015; 135:1065–1073.